The CSL Limited (ASX: CSL) share price has been a positive performer on Wednesday.
In afternoon trade, the biotherapeutics giant’s shares are up 2.5% to $277.12.
This compares favourably to a 0.1% decline by the ASX 200 index.
Why is the CSL share price rising today?
There have been a couple of catalysts for the rise in the CSL share price today.
One has been a legal breakthrough in the United States and the other is the release of a couple of bullish broker notes.
In respect to the former, according to the SMH, CSL and Grifols now have a right to appeal the banning of Mexican citizens from crossing the border to donate plasma. Its previous appeal to have the ban overturned was rejected, but that rejection was found to have been improperly dismissed.
And while there is no guarantee that the two parties will be able to successfully overturn the decision, it is a step in the right direction.
Also giving the CSL share price a boost today has been the release of broker notes out of Jefferies and Morgan Stanley.
Both brokers have retained the equivalent of buy ratings with $315 and $310 price targets, respectively.
Jefferies highlights that CSL’s impending shift to a new plasma collection system could be a big boost to sales and margins over the coming years. It commented: “We believe CSL has this relationship with Terumo exclusively for 4-5 years, and so these benefits are likely to be sustainable.”
Should you invest $1,000 in CSL right now?
Before you consider CSL, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.
The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of January 13th 2022
- 2 ASX shares at ‘appealing’ buy prices right now
- How did the CSL share price escape the carnage today?
- Macquarie picks ASX 200 shares to buy in this volatile environment
- 4 ‘defensive growth’ ASX shares to buy in turbulent times: Wilsons
- The CSL share price has tumbled 8% this year. Here’s why these top brokers still have faith
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL Ltd. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
from The Motley Fool Australia https://ift.tt/OuBFHdD